ATR vs LFCR
ATR: Global manufacturer of specialized dispensing, dosing, and packaging technologies serving pharmaceutical, beauty, personal care, and food/beverage markets with digital health integration. LFCR: Lifecore Biomedical is a specialized CDMO focused on complex sterile injectable fill-finish and manufacturing services for the pharmaceutical industry.
Side-by-side fundamentals
| Metric | ATR | LFCR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $129.17 | $4.58 | |
| Market cap as of 2026-07-23 | $8.2B | $174M | |
| P/E as of 2026-07-23 | 21.33 | n/a | |
| PEG as of 2026-07-23 | 2.83 | n/a | |
| Net margin as of 2026-07-23 | +10.0% | -26.5% | ATR higher |
| Gross margin as of 2026-07-23 | +36.7% | +30.0% | ATR higher |
| Operating margin as of 2026-07-23 | +13.5% | -1.9% | ATR higher |
| ROE as of 2026-07-23 | +14.4% | -126.8% | ATR higher |
| ROA as of 2026-07-23 | +7.6% | -18.9% | ATR higher |
| Debt / equity as of 2026-07-23 | 0.52 | 7.16 | ATR lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.9% | +27.6% | LFCR higher |
| Revenue CAGR (3y) SEC XBRL | +4.4% | +5.3% | LFCR higher |
| Dividend yield as of 2026-07-23 | +1.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.39 | 1.12 | |
| 1-year return as of 2026-07-22 close | -17.1% | -38.4% | ATR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.